Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
What is your preferred duration of aggrastat therapy, and does it differ if patient presented with NSTEMI versus STEMI?
Related Questions
What is your preferred intervention for diffuse severe ISR involving two layers of stent?
What neurologic and hemodynamic parameters do you use to determine candidacy for emergent cath lab activation following out of hospital cardiac arrest from VT/VF in patients with NSTEMI after ROSC has been achieved?
Under what circumstances would you consider withdrawing aspirin and continuing with potent P2Y12 inhibitor monotherapy after successful PCI in patients with acute coronary syndromes, based on the findings of the NEO-MINDSET trial?
What are your key takeaways regarding the difference in findings for BETA-MI DANBLOCK and REBOOT in patients post-MI with LVEF >40%?
Do you avoid high-potency P2Y12 inhibitors in favor of clopidogrel in patients with atrial fibrillation on a DOAC who undergo PCI?
Would acute-onset thrombocytopenia and concern for active bleeding with platelet count below 50,000 prompt you to hold plavix and/or aspirin following PCI that was done 1-2 weeks ago?
Would you continue SAPT beyond 12 months after left main stenting in an elderly patient on DOAC for paroxysmal atrial fibrillation?
What are your preferred guide catheters to use for engaging coronaries in patients with mechanical or bioprosthetic aortic valves?
What are your preferred femoral vascular closure devices for severely calcified femoral artery vessels following PCI, especially with higher sticks, and why?
What are your top takeaways from the updated ACS guidelines that will inform changes in clinical practice?
